Catalyst overview
Research summary
This catalyst tracks a Phase 3 update for Efgartigimod in Myositis. The expected timing is based on the latest available company guidance and may change.
ALKIVIA study: 11/20/24- Ph2 data established proof-of-concept. Enrollment to continue in Ph3 across all three subtypes (IMNM, ASyS, DM). 6/11/25- Presented new data at EULAR '25. 01/12/26:- ALKIVIA autoimmune inflammatory myopathies Phase 2/3 topline results in Q3 2026. 06/03/26:- ALKIVIA+ Week 52 interim data presented at EULAR 2026. ALKIVIA Ph2/3 topline expected Q3 2026. 08/17/26:- ALKIVIA Ph3 topline met primary endpoint in autoimmune myositis. Detailed results to be presented; timing TBA.
Verification
Confirm timing and program details against the company announcement or filing.